drugset / Trial / NCT00204776
XELOX for Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-label
Summary
Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |